SAB Biotherapeutics, Inc. (SABS) Institutional Ownership

Ownership Summary

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has 48 institutional investors with active 13F positions as of December 2025.

• These investors held 46.7% of outstanding shares in December 2025, up from 36.0% in September 2025.
• They increased total shares held in SAB Biotherapeutics by 37.82% from the prior quarter, while the number of investors in SABS increased 84.62% year over year.
• Among the 48 funds, 32 bought more SAB Biotherapeutics shares, 4 sold down, and 12 held their ground.
• The aggregate institutional position in SAB Biotherapeutics amounted to 36.37Mn shares as of December 2025, up by 9.98Mn shares quarter on quarter, and up 33.7Mn shares year over year.
• As of December 31, 2025, the biggest holder of SAB Biotherapeutics is Vivo Capital, LLC at 11.42Mn shares, representing 14.67% of shares outstanding.
• Leading buyers of SAB Biotherapeutics shares for the quarter ending December 2025 were Caligan Partners LP (7.97Mn), PERCEPTIVE ADVISORS LLC (5.63Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.41Mn), BALYASNY ASSET MANAGEMENT L.P. (3.28Mn), MILLENNIUM MANAGEMENT LLC (2.71Mn).
• Top sellers of SABS stock for the quarter ending December 2025 included Blackstone Inc. (1.28Mn), Simplify Asset Management Inc. (21.0K), OMERS ADMINISTRATION Corp (12.3K), Qube Research & Technologies Ltd (7.05K), Focus Partners Wealth (5.16K).
• Per Business Quant data, the top 10 holders of SAB Biotherapeutics for the quarter ending December 2025 are Vivo Capital, LLC (11.42Mn), Caligan Partners LP (7.97Mn), PERCEPTIVE ADVISORS LLC (6.43Mn), RA CAPITAL MANAGEMENT, L.P. (4.4Mn), Commodore Capital LP (4.4Mn), BALYASNY ASSET MANAGEMENT L.P. (3.76Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.41Mn), MILLENNIUM MANAGEMENT LLC (3.03Mn), Woodline Partners LP (2.85Mn), VANGUARD CAPITAL MANAGEMENT LLC (2.49Mn).